Published in Cell Cycle on March 03, 2016
Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16
The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med (2005) 5.95
A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res (2000) 4.62
Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes. Nature (1982) 4.30
NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res (2010) 4.10
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Structure and regulation of Src family kinases. Oncogene (2004) 3.44
Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophys Res Commun (2005) 3.31
Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?. Ann N Y Acad Sci (2009) 3.27
Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression. EMBO J (2000) 2.66
Inflammation and liver cancer: new molecular links . Ann N Y Acad Sci (2009) 2.29
Genetic mechanisms of hepatocarcinogenesis. Oncogene (2002) 2.21
Selected glimpses into the activation and function of Src kinase. Oncogene (2000) 2.16
GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. Cell Signal (2007) 2.11
Cell type-dependent pro- and anti-inflammatory role of signal transducer and activator of transcription 3 in alcoholic liver injury. Gastroenterology (2008) 1.90
Hepatic Akt activation induces marked hypoglycemia, hepatomegaly, and hypertriglyceridemia with sterol regulatory element binding protein involvement. Diabetes (2003) 1.86
Can growth hormone (GH) accelerate aging? Evidence from GH-transgenic mice. Neuroendocrinology (2003) 1.53
The growth hormone receptor: mechanism of activation and clinical implications. Nat Rev Endocrinol (2010) 1.44
Myc and cell cycle control. Biochim Biophys Acta (2014) 1.44
Metabolic effects of developmental, tissue-, and cell-specific expression of a chimeric phosphoenolpyruvate carboxykinase (GTP)/bovine growth hormone gene in transgenic mice. J Biol Chem (1990) 1.39
Growth allometry of the organs in giant transgenic mice. Endocrinology (1987) 1.32
The survival pathways phosphatidylinositol-3 kinase (PI3-K)/phosphoinositide-dependent protein kinase 1 (PDK1)/Akt modulate liver regeneration through hepatocyte size rather than proliferation. Hepatology (2009) 1.26
Histopathology associated with elevated levels of growth hormone and insulin-like growth factor I in transgenic mice. Endocrinology (1989) 1.25
GSK-3β: A Bifunctional Role in Cell Death Pathways. Int J Cell Biol (2012) 1.21
Signal transducer and activator of transcription 3 signaling within hepatocytes attenuates systemic inflammatory response and lethality in septic mice. Hepatology (2007) 1.14
Mechanisms limiting body growth in mammals. Endocr Rev (2011) 1.12
Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. Pharmacol Res (2015) 1.11
MYC and metabolism on the path to cancer. Semin Cell Dev Biol (2015) 1.09
In vivo regulation of growth hormone-stimulated gene transcription by STAT5b. Am J Physiol Endocrinol Metab (2004) 1.08
Mapping the growth hormone--Stat5b--IGF-I transcriptional circuit. Trends Endocrinol Metab (2012) 1.07
Growth inhibition in giant growth hormone transgenic mice by overexpression of insulin-like growth factor-binding protein-2. Endocrinology (2001) 1.05
Minireview: mechanisms of growth hormone-mediated gene regulation. Mol Endocrinol (2014) 1.04
Expression of insulin-like growth factor I in transgenic mice with elevated levels of growth hormone is correlated with growth. Endocrinology (1988) 1.03
In vivo targeting of the growth hormone receptor (GHR) Box1 sequence demonstrates that the GHR does not signal exclusively through JAK2. Mol Endocrinol (2009) 0.98
An agonist-induced conformational change in the growth hormone receptor determines the choice of signalling pathway. Nat Cell Biol (2008) 0.97
Growth-hormone-induced signal transducer and activator of transcription 5 signaling causes gigantism, inflammation, and premature death but protects mice from aggressive liver cancer. Hepatology (2012) 0.97
Cell cyclins: triggering elements of cancer or not? World J Surg Oncol (2010) 0.97
MAP kinase: it's been longer than fifteen minutes. Biochem Biophys Res Commun (2008) 0.96
High, persistent hepatocellular proliferation and apoptosis precede hepatocarcinogenesis in growth hormone transgenic mice. Liver (1999) 0.94
New murine model for hepatocellular carcinoma: transgenic mice expressing metallothionein-ovine growth hormone fusion gene. J Natl Cancer Inst (1990) 0.93
PI3K and AKT: Unfaithful Partners in Cancer. Int J Mol Sci (2015) 0.92
Actin cytoskeleton and beta-actin expression in correlation with higher invasiveness of selected hepatoma Morris 5123 cells. J Physiol Pharmacol (2006) 0.90
Crosstalk between growth hormone and insulin signaling. Vitam Horm (2009) 0.90
Increased levels of a unique post-translationally modified betaIVb-tubulin isotype in liver cancer. Biochemistry (2008) 0.90
Accelerated growth and visceral lesions in transgenic mice expressing foreign genes of the growth hormone family: an overview. Pediatr Nephrol (1991) 0.89
The expression of a metallothionein-ovine growth hormone fusion gene in transgenic mice does not impair fertility but results in pathological lesions in the liver. Endocrinology (1989) 0.89
Identification of a JAK2-independent pathway regulating growth hormone (GH)-stimulated p44/42 mitogen-activated protein kinase activity. GH activation of Ral and phospholipase D is Src-dependent. J Biol Chem (2002) 0.89
Translational control by oncogenic signaling pathways. Biochim Biophys Acta (2014) 0.89
Transgenic mice overexpressing GH exhibit hepatic upregulation of GH-signaling mediators involved in cell proliferation. J Endocrinol (2008) 0.86
Multiple consequences of human growth hormone expression in transgenic mice. Mol Biol Med (1989) 0.86
Hepatocellular alterations and dysregulation of oncogenic pathways in the liver of transgenic mice overexpressing growth hormone. Cell Cycle (2013) 0.85
mTOR in health and in sickness. J Mol Med (Berl) (2015) 0.85
Targeting RTK Signaling Pathways in Cancer. Cancers (Basel) (2015) 0.85
New insights into growth hormone receptor function and clinical implications. Horm Res (2008) 0.83
Suppression of growth hormone (GH) Janus tyrosine kinase 2/signal transducer and activator of transcription 5 signaling pathway in transgenic mice overexpressing bovine GH. Endocrinology (2004) 0.83
Hepatocellular kinetics and the expression of growth hormone (GH) in the livers and liver tumours of GH-transgenic mice. Tissue Cell (2002) 0.82
GH modulates hepatic epidermal growth factor signaling in the mouse. J Endocrinol (2009) 0.82
The biology of organ size determination. Diabetes Obes Metab (2008) 0.82
Effect of increased production of growth hormone on body composition in mice: transgenic versus control. J Endocrinol (1992) 0.82
Growth hormone signaling pathways. Growth Horm IGF Res (2015) 0.81
Growth hormone STAT5-mediated signaling and its modulation in mice liver during the growth period. Growth Horm IGF Res (2012) 0.80
Acute effects of human growth hormone on liver cells in vitro: a comparison with livers of mice transgenic for human growth hormone. Tissue Cell (1991) 0.77
Traditional and novel aspects of the metabolic actions of growth hormone. Growth Horm IGF Res (2015) 0.77
GH/STAT5 signaling during the growth period in livers of mice overexpressing GH. J Mol Endocrinol (2015) 0.76